Translate this page into:
Revisiting lumbar sympathectomy: Current indications and outcomes in peripheral arterial occlusive disease management
*Corresponding author: Suraj Pai, Department of Cardiovascular and Thoracic Surgery, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, Karnataka, India. drpaisuraj@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Pai S, Pai S, Lakshminarayanappa V. Revisiting lumbar sympathectomy: Current indications and outcomes in peripheral arterial occlusive disease management. Med India. doi: 10.25259/MEDINDIA_23_2025
Abstract
Lumbar sympathectomy (LS), whether performed surgically, laparoscopically, or through image-guided chemical neurolysis, was historically used to relieve pain and improve distal perfusion in patients with peripheral arterial occlusive disease (PAOD) who were not candidates for revascularization. With the advent of advanced endovascular and surgical revascularization techniques, the role of LS has narrowed considerably. This narrative review explores the historical evolution, mechanisms of action, various techniques, contemporary evidence, current indications, clinical outcomes, complications, and guideline recommendations regarding LS in the management of PAOD. High-quality randomized evidence supporting the use of LS, particularly in chronic limb-threatening ischemia (CLTI), is lacking. A Cochrane review found no eligible randomized controlled trials (RCTs) comparing LS with no treatment or among different LS techniques, while another found low-quality evidence favoring prostanoids over open LS in Buerger’s disease. However, recent retrospective studies on computed tomography-guided chemical LS and laparoscopic LS report meaningful relief of rest pain and short-term limb salvage in carefully selected, non-reconstructable patients, with low peri-procedural morbidity. Current guidelines do not advocate routine use of LS but recognize its palliative role in “no-option” CLTI. LS today is best considered an adjunctive, palliative measure for patients with CLTI who lack revascularization options, including those with Buerger’s disease, to relieve rest pain, promote minor ulcer healing, and potentially delay, or reduce the extent of amputation. Image-guided chemical or minimally invasive approaches are preferred . Prospective studies with standardized outcomes are needed to better define its role.
Keywords
Buerger’s disease
Chemical neurolysis
Chronic limb-threatening ischemia
Limb salvage
Lumbar sympathectomy
INTRODUCTION
Peripheral arterial occlusive disease (PAOD) is a progressive manifestation of systemic atherosclerosis and other vasculopathies, affecting the lower extremities and leading to a spectrum of clinical presentations ranging from asymptomatic disease to intermittent claudication and chronic limb-threatening ischemia (CLTI). CLTI, previously referred to as critical limb ischemia (CLI), is characterized by rest pain, ischemic ulcers, or gangrene, often resulting in significant morbidity, reduced quality of life, and a high risk of major amputation if not promptly managed.[1] The primary therapeutic goal in PAOD and CLTI is limb salvage and symptom relief through a combination of best medical therapy, lifestyle modification, and, whenever feasible, surgical or endovascular revascularization.[2,3]
Before the advent of modern vascular reconstruction techniques, lumbar sympathectomy (LS) was frequently employed as a primary therapeutic option. Introduced in the early 20th century, LS aimed to alleviate ischemic pain and improve distal perfusion by disrupting the lumbar sympathetic chain, thus reducing vasoconstrictive tone in the lower limbs.[4,5,6] During the mid-20th century, LS was considered the standard of care for patients with severe limb ischemia, particularly when revascularization options were limited or unavailable. However, its popularity waned in the 1970s and 1980s with the development of effective bypass surgeries, angioplasty, and later, endovascular interventions, which provided direct restoration of arterial blood flow.
Despite this decline, LS retains clinical relevance in selected patients – specifically, those with nonreconstructable PAOD or Buerger’s disease, where traditional revascularization strategies are either technically unfeasible or contraindicated. In such patients, LS can provide symptomatic relief, particularly rest pain reduction, and may support ulcer healing and minor tissue salvage. Recent advances in image-guided chemical LS and minimally invasive laparoscopic or retroperitoneoscopic techniques have renewed interest in sympathectomy, offering lower morbidity compared to traditional open approaches.[7,8]
Modern clinical guidelines, such as the Global Vascular Guidelines (GVG) (2019) and American Heart Association (AHA)/American College of Cardiology (ACC) Peripheral Arterial Disease (PAD) Guidelines (2024), no longer advocate routine LS but acknowledge its role as a palliative measure in carefully selected patients where other treatment modalities have failed. However, robust evidence supporting its efficacy remains limited, with most studies being observational and heterogeneous in nature. As a result, LS is primarily considered a last-resort adjunctive therapy aimed at improving quality of life, controlling ischemic rest pain, and potentially delaying major amputation.
This review revisits the role of LS in the modern management of PAOD, highlighting its historical significance, mechanisms of action, current indications, techniques, clinical outcomes, complications, and how it fits into current treatment algorithms.[9]
HISTORICAL PERSPECTIVE
The concept of LS originated in the early 20th century when the physiological role of the sympathetic nervous system in regulating peripheral vascular tone was increasingly recognized. In 1924, Leriche and Fontaine described the pathological triad of atherosclerotic occlusive disease, leading to early attempts at surgical sympathectomy to alleviate ischemic pain.[10,11] By interrupting the lumbar sympathetic chain, surgeons aimed to reduce vasoconstriction, thereby improving microcirculatory blood flow in ischemic limbs.
During the 1930s–1950s, LS became one of the mainstay treatments for PAD, especially in patients who presented with ischemic rest pain or non-healing ulcers but had no available reconstructive options. Early open surgical techniques were performed through extensive retroperitoneal approaches, often associated with significant perioperative morbidity, including bleeding and nerve injuries.[12,13,14] Nonetheless, LS was widely practiced, as revascularization techniques such as bypass surgery or endovascular interventions were not yet developed.
The 1960s and 1970s marked a pivotal period when the first major randomized controlled studies and observational series evaluated the outcomes of LS in comparison with emerging surgical revascularization techniques.[15] The results revealed that, although LS provided short-term pain relief, its effects on limb salvage were limited and often transient. Simultaneously, surgical bypass procedures, pioneered by DeBakey et al., demonstrated superior outcomes in terms of limb salvage and durability.[16] This led to a decline in the use of LS as a primary therapy.
The 1980s and 1990s saw further reductions in LS utilization due to the evolution of percutaneous transluminal angioplasty and other endovascular approaches. During this time, chemical LS using phenol or alcohol injections, often guided by fluoroscopy, gained popularity as a less invasive, outpatient alternative. This approach offered similar symptomatic benefits with fewer complications compared to open surgical techniques.
The advent of laparoscopic and retroperitoneoscopic LS in the late 1990s and early 2000s reignited interest in the procedure.[17,18] These minimally invasive approaches reduced hospital stay, operative morbidity, and recovery time, making LS a more attractive option for palliative therapy in patients unfit for revascularization.
In recent years, LS has been relegated to a niche role – used predominantly for:
Non-reconstructable CLTI in patients with diffuse distal disease
Buerger’s disease (thromboangiitis obliterans), where vasospasm plays a significant role
Pain palliation and ulcer healing in no-option cases.
Modern evidence, however, remains sparse and is largely derived from retrospective series and small trials, prompting organizations such as the GVG (2019) and ACC/AHA PAD Guidelines (2024) to limit LS recommendations to select palliative settings.
PATHOPHYSIOLOGIC RATIONALE
LS aims to modulate the sympathetic nervous system, which plays a pivotal role in regulating vascular tone, blood flow distribution, and microcirculatory dynamics. In PAOD, especially in advanced stages, sympathetically mediated vasoconstriction contributes to reduced skin perfusion, impaired tissue oxygenation, and ischemic pain.
Sympathetic innervation and vasoconstriction
The lumbar sympathetic chain, typically spanning L2–L4 ganglia, supplies vasoconstrictor fibers to the lower extremities. In ischemic conditions, heightened sympathetic activity aggravates peripheral vasospasm, further limiting microcirculatory blood flow in already compromised vascular territories.[19,20]
By interrupting the lumbar sympathetic chain, LS causes:
Arteriolar vasodilation: Reduction in vasoconstrictor tone increases skin blood flow
Improved capillary filling: Enhanced cutaneous perfusion may promote ulcer healing
Elevation of skin temperature: A clinical indicator of improved microvascular circulation.
Pain relief mechanisms
Rest pain in PAOD is partly due to ischemic neuropathy and the heightened sympathetic drive. LS helps relieve ischemic rest pain by:
Improving perfusion of ischemic nerves, reducing hypoxic pain signals
Interrupting pain transmission: Sympathetic fibers contribute to nociceptive pathways; their disruption can reduce pain perception.
Effects on microcirculation
While LS does not improve macrovascular flow, its effects on small resistance vessels and arterioles can increase skin perfusion pressure, especially when some degree of proximal arterial inflow remains. Transcutaneous oxygen tension (TcPO2) studies have shown post-sympathectomy improvements of 15–20 mmHg in selected patients.[21]
Collateral circulation and tissue healing
Some studies suggest LS may facilitate redistribution of blood flow toward the skin and distal tissues by reducing vasospasm in the cutaneous microcirculation. This can aid in:
Partial ulcer healing in ischemic digits
Delaying progression to major tissue loss, particularly in non-reconstructable disease.
Predictors of benefit
The therapeutic benefit of LS is most pronounced when:
Proximal blood flow is at least partially preserved (i.e., inflow vessels are not completely occluded)
Tissue loss is limited to minor ulcers or rest pain without gangrene extending above the forefoot
Vasospastic components (e.g., Buerger’s disease and diabetic microangiopathy) are prominent.
TECHNIQUES
LS can be performed through open surgical excision, minimally invasive laparoscopic or retroperitoneoscopic methods, or percutaneous chemical neurolysis. The choice of technique depends on patient fitness, availability of expertise, disease severity, and institutional resources.
Open LS
Historical gold standard
Open LS was the earliest form of the procedure, first popularized in the mid-20th century. The classic extraperitoneal approach involves direct exposure and removal of the L2–L4 sympathetic ganglia.
Procedure
A flank or midline retroperitoneal incision is made
The lumbar sympathetic chain is identified, dissected, and excised from the anterior surface of the vertebral bodies
The goal is to ensure complete interruption of pre- and postganglionic fibers supplying the lower extremities.
Advantages
Direct visualization allows precise ganglia removal
Durable results in terms of sympathetic denervation.
Disadvantages
Requires general anesthesia and carries higher morbidity (bleeding, ureteral or vascular injury, retrograde ejaculation in males)
Prolonged recovery compared with minimally invasive methods.
Laparoscopic and retroperitoneoscopic LS
Modern minimally invasive alternative
First introduced in the late 1990s, laparoscopic LS combines the efficacy of surgical sympathectomy with reduced invasiveness [Table 1].
| Technique | Approach | Anesthesia | Advantages | Limitations | Typical pain relief rate (%) |
|---|---|---|---|---|---|
| Open LS | Retroperitoneal open surgery | General anesthesia | Direct visualization; durable denervation | High morbidity; longer recovery | 60–70 |
| Laparoscopic LS | Minimally invasive surgery | General anesthesia | Reduced morbidity; shorter hospital stay | Requires surgical expertise; general anesthesia risks | 70–90 |
| Chemical LS | Image-guided injection (CT/fluoroscopy) | Local anesthesia | Outpatient; minimal invasiveness | Less durable; potential nerve regeneration | 50–80 |
LS: Lumbar sympathectomy, CT: Computed tomography.
Procedure
Performed under general anesthesia with the patient in the lateral decubitus or supine position
Ports are placed retroperitoneally or transperitoneally
A laparoscope is used to visualize the sympathetic chain along the vertebral column
Electrocoagulation, clipping, or excision is used to disrupt the chain (usually at L2–L4).
Benefits
Shorter hospital stay and faster recovery
Reduced post-operative pain and complications
Lower risk of major vascular or ureteral injuries due to improved visualization [Table 2].
| Indications | Details | Contraindications |
|---|---|---|
| No-option CLTI | Severe rest pain, non-healing minor ulcers; no revascularization feasible | Intermittent claudication |
| Buerger’s disease | Vasospastic distal disease refractory to prostanoids | Extensive tissue loss or gangrene |
| Palliative pain control | Intractable ischemic pain in end-stage disease | Complete arterial occlusion without collateral flow |
| Adjunct to wound healing | Minor ulcers with partial inflow | Significant comorbidities precluding intervention |
CLTI: Chronic limb-threatening ischemia.
Reported outcomes
Recent studies have demonstrated 80–90% rest pain relief and improved skin temperature post-laparoscopic LS in nonreconstructable CLTI, with minimal complications.
Chemical (image-guided) LS
Least invasive option
Chemical LS involves neurolytic destruction of lumbar sympathetic ganglia using agents such as absolute alcohol (95–100%) or phenol (5–7%), delivered under imaging guidance.
Procedure
Performed under local anesthesia in a prone or lateral position
Computed tomography (CT), fluoroscopy, or ultrasound guidance is used to localize the lumbar sympathetic chain (L2–L4)
A needle is advanced to the anterolateral surface of the vertebral body, and 5–10 mL of neurolytic agent is injected
Typically done bilaterally in staged sessions.
Advantages
Outpatient procedure with minimal recovery time
Avoids general anesthesia, making it suitable for high-risk patients
Can be repeated if symptoms recur.
Limitations
Less durable compared with surgical excision due to potential nerve regeneration
Rare complications include hypotension, neuralgia, or inadvertent spread of neurolytic agents.
Selection of technique
Surgical or laparoscopic LS is preferred when a durable result is desired and patient fitness allows general anesthesia [Table 3]
Chemical LS is favored for elderly or high-risk patients with no revascularization options
Many centers now perform chemical LS as the first-line palliative approach, reserving laparoscopic LS for refractory cases.
| Outcome | Reported range | Influencing factors | Comments |
|---|---|---|---|
| Rest pain relief | 50–90% | Technique, patient selection, and disease stage | Better in no-option CLTI and Buerger’s disease |
| Ulcer healing | 30–70% | Ulcer size, blood flow, and vasospasm presence | Partial healing; less effective in large wounds |
| Limb salvage | 40–60% (short-term) | Severity of ischemia, comorbidities | Mainly delays amputation; not curative |
| Complications | 5–15% | Surgical versus chemical method | Chemical LS safer but less durable |
CLTI: Chronic limb-threatening ischemia, LS: Lumbar sympathectomy
EVIDENCE SYNTHESIS
Systematic reviews and guidelines
A 2016 Cochrane review found no RCTs comparing LS with no treatment for non-reconstructable CLI.[1] Another review showed prostanoids outperforming open LS in Buerger’s disease. GVG (2019) and the ACC/AHA PAD guidelines (2024) emphasize revascularization and consider LS only as a palliative measure.
Observational data
Chahal et al. reported that CT-guided LS offered significant pain relief and acceptable limb salvage in selected patients.[3] Indian series using phenol neurolysis achieved >80% rest pain relief and ulcer healing, particularly when proximal inflow vessels remained patent. Laparoscopic LS studies confirm safety and symptom relief.
INDICATIONS IN 2025
With the advent of advanced endovascular and surgical revascularization techniques, the indications for LS have become highly selective and palliative. It is now largely reserved for patients with CLTI who are not candidates for revascularization due to anatomical, medical, or technical constraints.[22]
Current accepted indications
No-option CLTI
LS is recommended for patients with severe rest pain or non-healing ulcers who have no feasible surgical or endovascular revascularization options.
It can help relieve ischemic pain, improve cutaneous microcirculation, and, in some cases, promote minor ulcer healing.
Buerger’s disease (thromboangiitis obliterans)
Patients with distal vessel occlusion and vasospasm who are poor candidates for bypass or angioplasty may benefit from LS.
Chemical LS combined with prostanoid therapy (e.g., iloprost) is often employed for pain relief and ulcer healing.
Palliative pain management
LS can be considered in end-stage vascular disease patients with intractable rest pain where amputation is not desired or feasible.
Particularly helpful in high-risk elderly patients for whom general anesthesia and major limb procedures are contraindicated.
Adjunctive role in wound healing
In cases of minor ischemic ulceration, LS may improve skin temperature and TcPO2, creating a more favorable environment for wound healing.
Non-recommended indications
Intermittent claudication
Modern guidelines strongly discourage LS for intermittent claudication, as its benefit is negligible compared to exercise therapy and revascularization.
Major tissue loss or extensive gangrene
In advanced tissue loss (e.g., above forefoot or transmetatarsal level), LS is unlikely to salvage the limb and may only serve as a short-term pain control measure.
Guidelines and expert consensus
GVG (2019): LS is not recommended as a routine intervention but may be considered for no-option CLTI patients with severe ischemic pain
AHA/ACC PAD guidelines (2024): Recognize LS as a palliative measure, not a first-line treatment
Indian vascular surgery practice (2024): Reports continued use of chemical LS in high-risk Buerger’s disease patients, especially in low-resource settings where endovascular access is limited.
Patient selection criteria
Successful outcomes with LS in 2025 depend on careful patient selection, including:
Preserved proximal inflow (iliac and femoral vessels patent)
Presence of severe rest pain or small distal ulcers
Exclusion of patients with extensive necrosis where primary amputation is indicated
Failure of optimal medical therapy, including antiplatelets, statins, and vasodilators.
OUTCOMES
One of the primary therapeutic goals of LS in patients with PAOD is the alleviation of ischemic rest pain, which significantly impairs quality of life and often precedes tissue loss.
Mechanism of pain relief
LS achieves pain reduction by interrupting the sympathetic nerve fibers responsible for vasoconstriction and nociceptive signaling in the ischemic limb. This results in improved microcirculatory perfusion and diminished sympathetic-mediated pain transmission.
Clinical evidence
Studies consistently report significant rest pain relief in a substantial proportion of patients undergoing LS:
Open LS: Early observational studies from the mid-20th century demonstrated rest pain relief in approximately 60–70% of patients; however, effects were often transient and limited by procedure-related morbidity
Laparoscopic LS: More recent minimally invasive approaches report pain relief rates between 70% and 90%. Ahmed et al. reported sustained rest pain improvement in 85% of patients with non-reconstructable CLTI at 6-month follow-up. Similarly, Shaalan et al. documented an 80% pain relief rate post-laparoscopic LS
Chemical LS: CT- or fluoroscopy-guided chemical neurolysis with phenol or alcohol achieves rest pain reduction in approximately 50–80% of carefully selected patients. Kothari et al. reported over 80% immediate pain relief in patients with Buerger’s disease treated with chemical LS. Chahal et al. described durable pain control lasting up to 12 months in around 65% of cases.[3]
Duration and limitations
Pain relief following LS may persist from several months to over a year, but nerve regeneration can lead to symptom recurrence, particularly after chemical sympathectomy
LS is less effective in patients with extensive tissue necrosis or where macrovascular inflow is severely compromised, as improved microcirculation cannot compensate for total arterial occlusion.
Patient-reported outcomes
While quantitative data on quality of life are limited, reductions in rest pain translate to improved functional status and reduced analgesic requirements.[23] However, standardized pain scores and validated patient-reported outcome measures are lacking in most studies, highlighting the need for further research.
COMPLICATIONS
Open LS risks include bleeding, ureteral injury, and sexual dysfunction. Minimally invasive approaches have lower complication rates. Chemical LS may cause transient back pain, hypotension, or neuralgia [Table 4].
| Complication | Open LS | Laparoscopic LS | Chemical LS | Incidence (%) |
|---|---|---|---|---|
| Bleeding/Hematoma | Moderate to severe | Mild to moderate | Rare | 2–8 |
| Ureteral injury | Possible | Rare | Very rare | <1 |
| Sexual dysfunction (retrograde ejaculation) | Noted | Rare | Not reported | 1–5 |
| Neuralgia or neuropathic pain | Possible | Rare | Occasional | 3–7 |
| Hypotension | Occasionally reported | Rare | Possible (due to spread) | 1–3 |
| Infection | Moderate risk | Low risk | Very low | <2 |
LS: Lumbar sympathectomy
GUIDELINE POSITION
GVG 2019: No formal recommendation for LS due to insufficient evidence [Table 5].
ACC/AHA 2024 PAD guideline: LS may be considered as palliative therapy only when revascularization is impossible.
TASC II 2007: Recognized LS but now largely outdated.
| Guideline/organization | Year | Recommendation on LS for peripheral arterial occlusive disease | Level of evidence | Notes |
|---|---|---|---|---|
| GVG | 2019 | Palliative use only in no-option CLTI patients | Low (expert opinion) | Emphasizes revascularization first |
| AHA/ACC PAD Guideline | 2024 | LS is considered only when revascularization is impossible | Class IIb, Level C | Limited supporting data |
| TASC II | 2007 | Recognized LS role, now outdated | Low | Superseded by recent guidelines |
| Indian Vascular Society Practice | 2024 | Chemical LS for Buerger’s and no-option CLTI patients | Expert consensus | Common in resource-limited settings |
GVG: Global vascular guidelines, CLTI: Chronic limb-threatening ischemia, AHA: American Heart Association, ACC: American college of cardiology, PAD: Peripheral arterial, LS: Lumbar sympathectomy, disease, TASC: TransAtlantic Inter-Society Consensus.
CONCLUSION
LS remains a valuable palliative option for patients with PAOD who have no feasible revascularization alternatives. It offers significant relief of ischemic rest pain and may promote minor ulcer healing by improving microcirculatory blood flow. Minimally invasive chemical and laparoscopic techniques have reduced procedural risks and expanded their applicability. However, high-quality evidence supporting its long-term efficacy and impact on limb salvage is limited. Future well-designed studies are essential to better define its role alongside modern vascular interventions.
Author contributions:
Suraj Pai: Contributed to the conception and design of the study, data analysis, and drafting of the manuscript; Suresh Pai: Responsible for data collection, validation, and interpretation of results; Varsha Lakshminarayanappa: Contributed towards literature review, visualization, manuscript revision, and final proofreading. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.
Ethical approval:
Institutional Review Board approval is not required.
Declaration of patient consent:
Patient’s consent not required as there are no patients in this study.
Conflicts of interest:
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The authors confirm that they have used artificial intelligence (AI)-assisted technology solely for language refinement and to improve the clarity of writing. No AI assistance was employed in the generation of scientific content, data analysis or interpretation.
Financial support and sponsorship: Nil.
References
- Lumbar sympathectomy techniques for critical lower limb ischaemia due to nonreconstructable peripheral arterial disease. Cochrane Database Syst Rev. 2016;12:CD011519.
- [CrossRef] [PubMed] [Google Scholar]
- Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to nonreconstructable peripheral arterial disease. Cochrane Database Syst Rev. 2018;4:CD009366.
- [CrossRef] [PubMed] [Google Scholar]
- CT-guided lumbar sympathectomy as a last option for chronic limb-threatening ischemia of the lower limbs: Evaluation of Technical Factors and Long-Term Outcomes. AJR Am J Roentgenol. 2021;216:1273-82.
- [CrossRef] [PubMed] [Google Scholar]
- Lumbar chemical sympathectomy in peripheral vascular disease: Does it still have a role? Int J Surg. 2009;7:145-9.
- [CrossRef] [PubMed] [Google Scholar]
- Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69:3S-125.e40.
- [Google Scholar]
- 2024 ACC/AHA guideline on the management of lower extremity peripheral artery disease. A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024;149:e726-79.
- [Google Scholar]
- Inter-society consensus for the management of peripheral arterial disease (TASC II) J Vasc Surg. 2007;45:S5-67.
- [CrossRef] [PubMed] [Google Scholar]
- Chemical lumbar sympathectomy for ischemic rest pain. A randomized, prospective controlled clinical trial. Am J Surg. 1985;150:P341-5.
- [CrossRef] [PubMed] [Google Scholar]
- Lumbar sympathectomy in critical limb ischaemia: surgical, chemical or not at all? Cardiovasc Surg. 1999;7:200-2.
- [CrossRef] [PubMed] [Google Scholar]
- Effectiveness of lumbar sympathectomy in the treatment of occlusive peripheral vascular disease in lower limbs: Systematic review. Med Clin (Barc). 2010;134:477-82.
- [CrossRef] [PubMed] [Google Scholar]
- Evaluation of lumbar sympathectomy in peripheral arterial disorder of lower limbs. J Adv Zool. 2023;44:682.
- [Google Scholar]
- CT-guided lumbar sympathectomy: Results and analysis of factors influencing the outcome. Cardiovasc Intervent Radiol. 1998;21:319-23.
- [CrossRef] [PubMed] [Google Scholar]
- Is sympathectomy of benefit in critical leg ischaemia not amenable to revascularisation? Interact Cardiovasc Thorac Surg. 2003;4:478-83.
- [CrossRef] [PubMed] [Google Scholar]
- Retrospective evaluation of the effect of lumbar sympathetic blockade on pain scores, Fontaine classification, and collateral perfusion status in lower extremity PAD. Medicina (Kaunas). 2024;60:682.
- [CrossRef] [PubMed] [Google Scholar]
- Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to nonreconstructable peripheral arterial disease. Cochrane Database Syst Rev. 2018;4:CD009366.
- [CrossRef] [PubMed] [Google Scholar]
- Lumbar sympathectomy techniques for critical lower limb ischaemia due to nonreconstructable PAD. Cochrane Database Syst Rev. 2016;12:CD011519.
- [CrossRef] [PubMed] [Google Scholar]
- Lumbar sympathectomy can improve symptoms associated with ischaemia, vasculitis, diabetic neuropathy and hyperhidrosis affecting the lower extremities-a single-centre experience. Ir J Med Sci. 2018;187:1045-9.
- [CrossRef] [PubMed] [Google Scholar]
- Neurolytic lumbar sympathetic blockade: Duration of denervation and relief of rest pain. Anesthesia Intensive Care. 1979;7:121-35.
- [CrossRef] [PubMed] [Google Scholar]
- Phenol sympathectomy in the treatment of intermittent claudication: A controlled clinical trial. Br J Surg. 1975;62:68-71.
- [CrossRef] [PubMed] [Google Scholar]
- Influence of lumbar sympathectomy on the proportion of amputation (author's transl)] Acta Chir Belg. 1977;76:131-2.
- [Google Scholar]
- Lumbar sympathectomy for severe lower limb ischaemia: Results and analysis of factors influencing the outcome. J Cardiovasc Surg (Torino). 1988;29:310-4.
- [Google Scholar]
- Lumbar sympathectomy in end-stage arterial occlusive disease. Ann Surg. 1976;183:157-60.
- [CrossRef] [PubMed] [Google Scholar]
- Chemical lumbar sympathectomy in severe lower limb ischaemia. Ulster Med J. 1994;63:137-43.
- [Google Scholar]